Benzinga | Nov 5, 2021 10:41AM EDT

Raymond James Maintains Strong Buy on NGM Biopharmaceuticals, Raises Price Target to $42

Raymond James analyst Steven Seedhouse maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Strong Buy and raises the price target from $39 to $42.